首页> 外文期刊>European Journal of Medicinal Chemistry: Chimie Therapeutique >Synthesis and in vitro antitumor activity of substituted quinazoline and quinoxaline derivatives: search for anticancer agent.
【24h】

Synthesis and in vitro antitumor activity of substituted quinazoline and quinoxaline derivatives: search for anticancer agent.

机译:取代的喹唑啉和喹喔啉衍生物的合成及其体外抗肿瘤活性:寻找抗癌药。

获取原文
获取原文并翻译 | 示例
           

摘要

The synthesis of some 2-furano-4(3H)-quinazolinones, diamides (open ring quinazolines), quinoxalines and their biological evaluation as antitumor agents using National Cancer Institute (NCI) disease oriented antitumor screen protocol are investigated. Among the synthesize compounds, seventeen compounds were granted NSC code and screened at National Cancer Institute (NCI), USA for anticancer activity at a single high dose (10(-5) M) in full NCI 60 cell panel. Among the selected compounds, 3-(2-chloro benzylideneamine)-2-(furan-2-yl) quinazoline-4(3h)-one 21 was found to be the most active candidate of the series at five dose level screening against Ovarian OVCAR-4 and Non-small cell lung cancer NCI-H522 with GI50 1.82 & 2.14 muM respectively. Rational approach and QSAR techniques enabled the understanding of the pharmacophoric requirement for quinazoline, diamides and quinoxaline derivatives.
机译:使用国家癌症研究所(NCI)疾病导向的抗肿瘤筛选方案,研究了某些2-furano-4(3H)-喹唑啉酮,二酰胺(开环喹唑啉),喹喔啉的合成及其作为抗肿瘤剂的生物学评估。在合成的化合物中,有17种化合物被授予NSC代码,并在美国国家癌症研究所(NCI)进行了筛选,以在完整的NCI 60细胞组中以单次高剂量(10(-5)M)进行抗癌活性。在所选的化合物中,发现三(2-氯苄亚胺)-2-(呋喃-2-基)喹唑啉-4(3h)-21是针对卵巢癌的五个剂量水平筛选系列中最活跃的候选化合物OVCAR-4和非小细胞肺癌NCI-H522的GI50分别为1.82和2.14μM。合理的方法和QSAR技术使人们能够理解喹唑啉,二酰胺和喹喔啉衍生物的药效学要求。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号